GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Debt-to-Asset

VGI Health Technology (XNEC:VTL) Debt-to-Asset : 0.00 (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Debt-to-Asset?

VGI Health Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil. VGI Health Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil. VGI Health Technology's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in . 20 was A$0.00 Mil.

VGI Health Technology Debt-to-Asset Historical Data

The historical data trend for VGI Health Technology's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Debt-to-Asset Chart

VGI Health Technology Annual Data
Trend
Debt-to-Asset

VGI Health Technology Semi-Annual Data
Debt-to-Asset

Competitive Comparison of VGI Health Technology's Debt-to-Asset

For the Biotechnology subindustry, VGI Health Technology's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Debt-to-Asset falls into.


VGI Health Technology Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

VGI Health Technology's Debt-to-Asset for the fiscal year that ended in . 20 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=( + ) /
=N/A

VGI Health Technology's Debt-to-Asset for the quarter that ended in . 20 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=( + ) /
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VGI Health Technology  (XNEC:VTL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

VGI Health Technology Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Debt-to-Asset
Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
Website
https://www.vgiht.com
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines